ProCE Banner Activity

FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Clinical Thought

In this commentary, expert faculty address frequently asked questions about novel HER3-targeted agents in development for the treatment of patients with NSCLC, including recent trial data and implications for clinical practice.

Released: May 25, 2023

Share

Faculty

Yasushi Goto

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Yasushi Goto, MD, PhD

Assistant Chief 
Department of Thoracic Oncology 
National Cancer Center Hospital Japan
Tokyo, Japan 

Yasushi Goto, MD, PhD: consultant/advisor/speaker: Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Lilly, Merck, MSD, Novartis, Ono, Pfizer, Thermo Fisher; research grants (paid to institution): AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Kyorin, Lilly, Novartis, Ono, Pfizer, Preferred Network; research grants (paid to clinical trial group): AZK, Pfizer; advisory board: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Guardant Health, Illumina, Lilly, MSD, Novartis, Ono, Pfizer, Taiho.

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Blueprint, Daiichi Sankyo, Janssen, Taiho.